ClinicalTrials.gg
RecruitingNCT06883526Updated Jan 5, 2026

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

A Phase 1/2 interventional study of ZG005 for Injection and Gecacitinib Hydrochloride Tablets in Lymphoma, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 275 studies in Lymphoma with a site in China — 102 open to participants now, 118 under way, 10 of them phase 3. Lymphoma · China.

Planned enrollment
95th of 232
60 · median 47
Started
2025
with 24 others
Phase 1/2
55 of 275
24 open now
Primary completion
2027-04
later than 72 of 117 live
Registered
236th of 275
by date

Among the 275 studies in Lymphoma with a site in China, this one is the 95th largest by planned enrollment of the 232 interventional ones that give a count, is one of 25 that started in 2025, is one of 55 in phase 1/2, reaches primary completion later than 72 of the 117 other live ones, and was the 236th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

102 of the 275 studies in Lymphoma with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Lymphoma with a site in China, or all of them as a file.
02

Study summary

PART 1:

  1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
  2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma.

PART 2:

To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understand this study and voluntarily sign the ICF;
  • Age ≥18 at ICF signing, regardless of gender;
  • confirmed lymphoma.

Exclusion criteria

Exclusion Criteria:

  • Lymphoma with known CNS involvement;
  • Severe cardiovascular/cerebrovascular diseases.
  • Any other reason deeming the participant unsuitable for the study, as judged by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Part 1: Plan A

    ZG005(20mg/kg Q3W)+Gecacitinib(Gecacitinib is administered continuously until the end of treatment)

    Biological: ZG005 for Injection · Drug: Gecacitinib Hydrochloride Tablets

  • Experimental
    Part 1: Plan B

    ZG005(20mg/kg Q3W)+Gecacitinib(Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21)

    Biological: ZG005 for Injection · Drug: Gecacitinib Hydrochloride Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Time frame: Up to 2 years

Secondary outcomes

  1. Immunogenicity

    Incidence of antidrug antibodies (ADA)

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Apr 2027, 23 months after the start.

Of 66 industry-sponsored phase 1/2 interventional studies under Lymphoma, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 87. This study's planned 23 months is below that.

Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Mar 19, 2025
StartActual
May 16, 2025
Primary completionEst.
Apr 2027
CompletionEst.
May 2027
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06883526
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
May 16, 2025
Primary completion
Apr 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jan 5, 2026

Study contacts

Shuangyu Jia
Contact
jiasy@zelgen.com
+86-0512-57018310
Jason Wu
study chair · Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nilvanstomig · Jaktinib

Start the discussion